Return to content in this issue

 

Early Effectiveness of Dupilumab in Patients With Type 2 Severe Asthma: A Prospective Real-Life Study

Castilla-Martínez M1, Andújar-Espinosa R2,3, Flores-Martín I4, Reyes Cotes MH5, Cabrejos-Perotti S6, Miralles-López JC7, Carbonell-Martínez A8, Bravo-Gutierrez FJ9, Valverde-Molina J10, Pérez-Fernández V11, RE-ASGRAMUR GROUP*

1Pulmonology Department, University General Hospital Los Arcos, San Javier, Murcia, Spain
2Pulmonology Department, University Clinic Hospital Virgen de la Arrixaca, Murcia, Spain
3Medicine Department, University of Murcia, Murcia, Spain
4Allergy Department, University General Hospital Santa Lucía, Cartagena, Murcia, Spain
5Pulmonology Department, Northwest County Hospital, Caravaca, Murcia, Spain
6Allergy Department, General Hospital Rafael Méndez, Lorca, Murcia, Spain
7Allergy Department, University General Hospital Reina Sofía, Murcia, Spain
8Allergy Department, La Fama Medical Center, Murcia, Spain
9Pulmonology Department, University General Hospital Santa Lucía, Cartagena, Murcia, Spain
10Pediatrics Department, University General Hospital Santa Lucía, Cartagena, Murcia, Spain
11Department of Public Health Sciences, University of Murcia School of Medicine, Murcia, Spain
*Members of the RE-ASGRAMUR (Register of Severe Asthma of the Region of Murcia) Group are listed in Supplementary Appendix 1.

J Investig Allergol Clin Immunol 2023; Vol 33(2) : 126-128
doi: 10.18176/jiaci.0872

Key words: Severe asthma, Dupilumab, Real-life, T2 inflammation